Effect of three months’ treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31 793 patients

References

• Arauz-Pacheco C, et al. Treatment of hypertension in adults with diabetes. American Diabetes Association position statement. Diabetes Care 2003;26\(Suppl 1):S80–2
   Google Scholar
• Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19(5):403–18
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT. Diabetes and hypertension. Diabetes Care 2001;24:1679–84
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011–53
   PubMed Web of Science ®Google Scholar
• Sharma AM, et al. High prevalence and poor control of hyper-tension in primary care: cross-sectional study. J Hypertens 2004;22(3):479–86
   PubMed Web of Science ®Google Scholar
• Pittrow D, Wittchen H, Kirch W. Hypertension and diabetes care among primary care doctors in Germany: results from an epidemiological cross-sectional study. In: Kirch W, editor. Public health in Europe. Berlin: Springer-Verlag; 2004. p. 203–18
   Google Scholar
• Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial [HOT Study Group]. Lancet 1998; 351(9118):1755–62
   PubMed Web of Science ®Google Scholar
• Hansson L, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354(9192):1751–6
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317(7160):703–13
   Google Scholar
• Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138(7):593–602
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352(9131): 837–53
   Google Scholar
• Vijan S, Hofer TP, Hayward RA. Estimated benefits of glycemic control in microvascular complications in type 2 diabetes. Ann Intern Med 1997;127(9):788–95
   Google Scholar
• Fogari R, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring [Irbesartan Multicenter Investigators’ Group]. J Hypertens 1997;15(12 Pt 1):1511–8
   Google Scholar
• Raskin P, et al. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999;13(10):683–7
   PubMed Web of Science ®Google Scholar
• Larochelle P, et al. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension [Irbesartan Multi-center Investigators]. Am J Cardiol 1997;80(12):1613–5
   PubMed Web of Science ®Google Scholar
• Stumpe KO, et al. Comparison of the angiotensin-II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998;7(1):31–7
   PubMedGoogle Scholar
• Parving HH, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New Engl J Med 2001;345(12):870–8
   PubMed Web of Science ®Google Scholar
• Lewis EJ, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New Engl J Med 2001;345(12):851–60
   PubMed Web of Science ®Google Scholar
• Chobanian AV, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. J Am Med Assoc 2003;289(19):2560–72
   PubMed Web of Science ®Google Scholar
• Hypertension in people with Type 2 diabetes: knowledge-based diabetes-specific guidelines. Diabet Med 2003; 20(12):972–87
   PubMed Web of Science ®Google Scholar
• SAS and C. SAS Institute Inc., NC, 1999
   Google Scholar
• Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16 600 patients in primary care. Curr Med Res Opin 2004;20(10):1625–31
   Google Scholar
• Lehnert H, et al. Regression of microalbuminuria in type 2 diabetics after switch to irbesartan treatment. An observational study in 38 016 patients in primary care. Clin Drug Invest 2004;24:217–25
   PubMed Web of Science ®Google Scholar
• Adler AI, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000;321(7258):412–9
   PubMed Web of Science ®Google Scholar
• Bakris GL, et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med 2003;163(13):1555–65
   PubMed Web of Science ®Google Scholar
• Puchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin-II antagonist. J Hypertens Suppl 2001;19(Suppl 1):S41–8
   Google Scholar
• Conlin PR, et al. Angiotensin-II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13(4 Pt 1):418–26
   Google Scholar
• Franklin SS, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96(1):308–15
   PubMed Web of Science ®Google Scholar
• Gasowski J, et al. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. J Hypertens 2002;20(1):145–51
   PubMed Web of Science ®Google Scholar
• Blacher J, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000;160(8):1085–9
   PubMed Web of Science ®Google Scholar
• Scholze J. Pulse pressure in the therapeutic management of hypertension? [In German]. Herz 2004;29(3):276–89
   PubMedGoogle Scholar
• Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000;160(16):2447–52
   Google Scholar
• Croom KF, et al. Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs 2004;64(9):999–1028
   PubMed Web of Science ®Google Scholar
• Schulte K, Fischer M, Meyer-Sabellek W. Efficacy and tolerability of candesartan cilexetil monotherapy or in combination with other antihypertensive drugs: results of the AURA study. Clin Drug Invest 1999;18:453–60
   Google Scholar
• Scholze J, et al. Valsartan alone and in combination with hydro-chlorothiazide in general practice: results from two postmarketing surveillance studies involving 54 928 patients with essential hypertension. Clin Drug Invest 2000;20:1–7
   Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342(25):1887–92
   Google Scholar